MENU
INTS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Intensity Therapeutics (INTS) Ownership - Who owns Intensity Therapeutics?

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers... Show more

Profile

Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
30.61M
P/E Ratio
N/A
Total Cash
2.22M
Projected Growth
N/A
Total Debt
125K
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
0.04
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

INTS
Capitalization
30.6M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
2.22M
Total Cash/Share
0.04
Total Debt
125K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
2.18M
P/B Ratio
4.24
Cash Flow
N/A
Earnings
-0.82
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
3K
Current Ratio
1.40
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-12.56M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-191.80
Shares Held By Institutions
338K
Shares Outstanding - Current
60.1M
Total Liabilities
2.26M
Total Volume MTD
N/A
Value
1
Gain YTD
-70.909
View a ticker or compare two or three
INTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. INTS showed earnings on November 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com